生命を脅かす静脈動脈不全の新たなリスク予測スコアの開発と検証
関連する実験動画
Updated: Jan 24, 2026

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.5K
Karim Wahbi1,2, Rabah Ben Yaou3,4, Estelle Gandjbakhch5,6,7
1APHP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris-Descartes, Sorbonne Paris Cité University (K.W., D.D.).
Circulation
|June 4, 2019
まとめ
この研究は,LMNA変異の患者における生命を脅かす心房不律症 (VTA) のリスク予測モデルを開発した. このモデルは,現在のガイドラインを上回る,埋め込み可能な心臓変容器-除細動器の選択を改善します.
科学分野:
- 心臓病科
- 遺伝学
- 医療情報学
背景:
- LMNA変異の患者では,生命を脅かす静脈動脈動脈症 (LTVTA) のリスクの正確な分層化は極めて重要です.
- インプラント可能な心房変圧器 (ICD) のインプラント候補者を特定するには,正確なLTVTAリスク評価が必要です.
研究 の 目的:
- LMNA変異を有する患者のLTVTAを予測するための予後モデルを開発し,検証する.
- ICDの選択のための現在の臨床実践ガイドラインとモデルのパフォーマンスを比較する.
主な方法:
- LMNA変異を有する839人の成人の患者群を660人の誘導サンプルと179人の検証サンプルで分析した.
- LTVTAは突然の心臓死,ICDで治療されたVTA,または血液動力学的に不安定なVTAと定義された.
- 予測モデルを導き出すためにFine-Gray回帰モデルを使用し,ガイドラインに対して再分類の純改善が評価されました.
主要な成果:
- 最終モデルでは,LTVTAの予測因子として,男性性,非ミッセンスのLMNA変異,心房閉塞,持続しない心房短拍,および左心房放出率の低下が特定されました.
- このモデルは,導出 (C指数0.776) と検証 (C指数0.800) の両方のサンプルで良好な差別性を示した.
- 5年リスクの値≥7%は,LTVTAイベントの96. 2%を予測し,ガイドラインよりも28. 8%の純再分類改善を達成しました.
結論:
- 開発されたリスク予測モデルは,ラミノパシー患者のICD移植に適した候補者を選択するのに有意に役立ちます.
- このツールは,LTVTAのリスク評価における現在の標準的な治療法と比較して,より正確で効果的なアプローチを提供します.
関連する概念動画
Reliability and Validity
13.8K
Reliability and validity are two important considerations that must be made with any type of data collection. Reliability refers to the ability to consistently produce a given result. In the context of psychological research, this would mean that any instruments or tools used to collect data do so in consistent, reproducible ways.
13.8K
Half-life of a Reaction
38.8K
The half-life of a reaction (t1/2) is the time required for one-half of a given amount of reactant to be consumed. In each succeeding half-life, half of the remaining concentration of the reactant is consumed. For example, during the decomposition of hydrogen peroxide, during the first half-life (from 0.00 hours to 6.00 hours), the concentration of H2O2 decreases from 1.000 M to 0.500 M. During the second half-life (from 6.00 hours to 12.00 hours), the concentration decreases from 0.500 M to...
38.8K
Characteristics of Life
257.3K
Biology is a natural science that studies life and living organisms, including their structure, function, development, interactions, evolution, distribution, and taxonomy. The field's scope is extensive and divided into several specialized disciplines, such as anatomy, physiology, ethology, genetics, and many more. All living things share a few key traits, including cellular organization, heritable genetic material and the ability to adapt/evolve, metabolism to regulate energy needs, the...
257.3K
Dysrhythmias II: Classification of Tachyarrhythmias
520
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
520
The Angiosperm Life Cycle
72.2K
Plants have a life cycle split between two multicellular stages: a haploid stage—with cells containing one set of chromosomes—and a diploid stage—with cells containing two sets of chromosomes. The haploid stage is the gamete-producing gametophyte, and the diploid stage is the spore-producing sporophyte.
72.2K
In Vitro Drug Release Testing: Overview, Development and Validation
323
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
323

